Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates

Vaccine

Volumn 24, Issue 17, 2006, Pages 3490-3499

  Mascarell, Laurent ^a,b   Bauche, Cecile ^a   Fayolle, Catherine ^a,b   Diop, Ousmane M ^c   Dupuy, Monique ^d   Nougarede, Nolwenn ^d   Perraut, Ronald ^c   Ladant, Daniel ^a   Leclerc, Claude ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE DAKAR   (Senegal)

^d SANOFI PASTEUR   (France)

Author keywords

Adenylate cyclase; HIV Tat; Neutralizing antibodies; Non human primates

Indexed keywords

ADENYLATE CYCLASE; NEUTRALIZING ANTIBODY; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CERCOPITHECIDAE; DENDRITIC CELL; DRUG PROTEIN BINDING; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IN VITRO STUDY; MALE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; TH1 CELL;

ADENYLATE CYCLASE; AIDS VACCINES; ANIMALS; ANTIGENS, CD11B; CELL POLARITY; CERCOPITHECUS AETHIOPS; DENDRITIC CELLS; FEMALE; GENE PRODUCTS, TAT; HIV ANTIBODIES; HIV-1; HUMANS; INTERFERON TYPE II; MALE; TH1 CELLS;

EID: 33645243587     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.02.009     Document Type: Article

References (52)

1. Y. Wu, and J.W. Marsh Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA Science 293 5534 2001 1503 1506
2. B. Bnsoli, G. Barillari, S.Z. Salahuddin, R.G. Gallo, and F. Wong-Staal Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients Nature 345 6270 1990 84 86
3. B. Bnsoli, L. Buonaguro, and G. Barillari Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation J Virol 67 1 1993 277 287
4. A.D. Frankel, and G.O. Patio Cellular uptake of the tat protein from human immunodeficiency virus Cell 55 6 1988 1189 1193
5. B. Fanales-Belasio, S. Moretti, and F. Nappi Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses J Immunol 168 1 2002 197 206
6. B. Izmailova, F.M. Bertley, and Q. Huang HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages Nat Med 9 2 2003 191 197
7. L. Huang, I. Bosch, W. Hofmann, J. Sodroski, and A.B. Pardee Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains J Virol 72 11 1998 8952 8960
8. P. Secchiero, D. Zella, S. Gapitani, R.G. Gallo, and G. Zauli Extracellular HIV-1 tat protein up-regulates the expression of surface GXG-chemokine receptor 4 in resting GD4 + T cells J Immunol 162 4 1999 2427 2431
9. M.G. Re, M. Vignoli, and G. Furlini Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients J Glin Virol 21 1 2001 81 89
10. P. Reiss, J.M. Lange, and A. de Ronde Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1 J Med Virol 30 3 1990 163 168
11. J.F. Zagury, A. Sill, and W. Blattner Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine J Hum Virol 1 4 1998 282 292 [see comments]
12. B. Gaselli, M. Betti, and M.P. Grossi DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat J Immunol 162 9 1999 5631 5638
13. S. Borsutzky, V. Fiorelli, and T. Bbensen Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant Eur J Immunol 33 6 2003 1548 1556
14. A. Cafaro, A. Gaputo, and G. Fracasso Control of SHIV-89, 6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine Nat Med 5 6 1999 643 650
15. A. Cafaro, A. Caputo, and M.T. Maggiorella SHIV89, 6P pathogenicity in eynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine J Med Primatol 29 3-4 2000 193 208
16. G. Goldstein, K. Manson, G. Tribbick, and R. Smith Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33) Vaccine 18 25 2000 2789 2795
17. C.D. Pauza, P. Trivedi, and M. Wallace Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques Proc Nat Acad Sci USA 97 7 2000 3515 3519
18. M.W. Richardson, J. Mirchandani, and P. Silvera Immunogenicity of HIV-1 IIIB and SHIV 89, 6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses DNA Cell Biol 21 9 2002 637 651
19. P. Silvera, M.W. Richardson, and J. Greenhouse Outcome of simian-human immunodeficiency virus strain 89, 6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein J Virol 76 8 2002 3800 3809
20. G. Belliard, B. Hurtrel, and B. Moreau Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides Vaccine 23 11 2005 1399 1407
21. P. Guermonprez, N. Khelef, and B. Blouin The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha (M)beta (2) integrin (CD11b/CD18) J Bxp Med 193 9 2001 1035 1044
22. D. Ladant, and A. Ullmann Bordatella pertussis adenylate cyclase: a toxin with multiple talents Trends Microbiol 7 4 1999 172 176
23. C. Fayolle, P. Sebo, D. Ladant, A. Ullmann, and C. Leclerc In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8 + T cell epitopes J Immunol 156 12 1996 4697 4706
24. G. Karimova, C. Fayolle, S. Gmira, A. Ullmann, C. Leclerc, and D. Ladant Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8 (+) T cell epitopes into antigen-presenting cells Proc Natl Acad Sci USA 95 21 1998 12532 12537
25. P. Guermonprez, D. Ladant, G. Karimova, A. Ullmann, and C. Leclerc Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway J Immunol 162 4 1999 1910 1916
26. * 0201-restricted melanoma epitopes Int Immunol 15 12 2003 1423 1430
27. M.F. Saron, C. Fayolle, P. Sebo, D. Ladant, A. Ullmann, and C. Leclerc Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8 + T cell epitope from lymphocytic choriomeningitis virus Proc Natl Acad Sci USA 94 7 1997 3314 3319
28. G. Fayolle, D. Ladant, G. Karimova, A. Ullmann, and G. Leclerc Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope J Immunol 162 7 1999 4157 4162
29. G. Fayolle, A. Osickova, and R. Osicka Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity J Virol 75 16 2001 7330 7338
30. G. Dadaglio, Z. Moukrim, R. Lo-Man, V. Sheshko, P. Sebo, and G. Leclerc Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis Infect Immun 68 7 2000 3867 3872
31. J. Loucka, G. Schlecht, J. Vodolanova, G. Leclerc, and P. Sebo Delivery of a MalB CD4 (+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase Infect Immun 70 2 2002 1002 1005
32. G. Schlecht, J. Loucka, H. Najar, P. Sebo, and G. Leclerc Antigen targeting to GDI 1b allows efficient presentation of GD4 + and GD8 + T cell epitopes and in vivo Th1-polarized T cell priming J Immunol 173 10 2004 6089 6097
33. G. Fayolle, G. Bauche, D. Ladant, and G. Leclerc Bordetella pertussis adenylate cyclase delivers chemically coupled GD8 + T-cell epitopes to dendritic cells and elicits GTL in vivo Vaccine 23 5 2004 604 614
34. L. Mascarell, G. Fayolle, G. Bauche, D. Ladant, and G. Leclerc Induction of neutralizing antibodies and Th1-polarized and GD4-independent GD8 + T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis J Virol 79 15 2005 9872 9884
35. T.G. VanCott, F.R. Bethke, and V.R. Polonis Dissociation rate of antibody-gpl20 binding interactions is predictive of V3-mediated neutralization of HIV-1 J. Immunol 153 1994 449 459
36. M. El-Azami-El-Idrissi, G. Bauche, and J. Loucka Interaction of Bordetella pertussis adenylate cyclase with GD11b/GD18: role of toxin acylation and identification of the main integrin interaction domain J Biol Ghem 278 40 2003 38514 38521
37. X. PrevLlle, D. Ladant, B. Timmerman, and G. Leclerc Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate gyclase carrying the human PapillomavLrus 16 E7 oncoprotein Cancer Res 65 2 2005 641 649
38. P. Jeannin, T. Renno, and L. Goetsch OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHG class I presentation pathway Nat Immunol 1 6 2000 502 509
39. L.C. Bonifaz, D.P. Bonnyay, and A. Charalambous In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination J Exp Med 199 6 2004 815 824
40. W.J. Krone, G. Debouck, L.G. Epstein, P. Heutink, R. Meloen, and J. Goudsmit Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo J Med Virol 26 3 1988 261 270
41. M. Tahtinen, A. Ranki, S.L. Valle, V. Ovod, and K. Krohn B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains Biomed Pharmacother 51 10 1997 480 487
42. D.A. Brake, J. Goudsmit, and W.J. Krone Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1 J Virol 64 2 1990 962 965
43. W.W. Cruikshank, S.R. Doctrow, and M.S. Falvo A lipidated anti-Tat antibody enters living cells and blocks HIV-1 viral replication J Acquir Immune Defic Syndr Hum Retrovirol 14 3 1997 193 203
44. A.M. Mhashilkar, J. Bagley, S.Y. Chen, A.M. Szilvay, D.G. Helland, and W.A. Marasco Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies EMBO J 14 7 1995 1542 1551
45. M.B. Jordan, D.M. Mills, J. Kappler, P. Marrack, and J.G. Cambier Promotion of B cell immune responses via an alum-induced myeloid cell population Science 304 5678 2004 1808 1810
46. T.R. Mosmann, and S. Sad The expanding universe of T-cell subsets: Th1, Th2 and more Immunol Today 17 3 1996 138 146
47. M. Clerici, and G.M. Shearer A TH1 → TH2 switch is a critical step in the etiology of HIV infection Immunol Today 14 3 1993 107 111
48. M. Clerici, F.T. Hakim, and D.J. Venzon Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals J Clin Invest 91 3 1993 759 765
49. Y. Becker The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers - a review and hypothesis Virus Genes 28 1 2004 5 18
50. D.L. Confer, and J.W. Baton Bordetella adenylate cyclase: host toxicity and diagnostic utility Dev Biol Stand 61 1985 3 10
51. Z. Farfel, S. Konen, B. Wiertz, R. Klapmuts, P.A. Addy, and B. Hanski Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccination J Med Microbiol 32 3 1990 173 177
52. J.L. Arciniega, B.L. Hewlett, and F.D. Johnson Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis J Infect Dis 163 1 1991 135 142